Becton Dickinson PE Ratio 2010-2025 | BDX
Current and historical p/e ratio for Becton Dickinson (BDX) from 2010 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Becton Dickinson PE ratio as of June 04, 2025 is 12.11.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Becton Dickinson PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2025-06-04 |
170.94 |
|
32.62 |
| 2025-03-31 |
229.06 |
$5.24 |
43.71 |
| 2024-12-31 |
225.84 |
$6.02 |
37.52 |
| 2024-09-30 |
238.87 |
$5.94 |
40.21 |
| 2024-06-30 |
230.61 |
$4.86 |
47.45 |
| 2024-03-31 |
243.20 |
$4.54 |
53.57 |
| 2023-12-31 |
238.68 |
$4.22 |
56.56 |
| 2023-09-30 |
252.04 |
$4.96 |
50.81 |
| 2023-06-30 |
256.50 |
$5.51 |
46.55 |
| 2023-03-31 |
239.63 |
$5.33 |
44.96 |
| 2022-12-31 |
245.22 |
$5.30 |
46.27 |
| 2022-09-30 |
214.08 |
$5.88 |
36.41 |
| 2022-06-30 |
236.06 |
$5.80 |
40.70 |
| 2022-03-31 |
247.65 |
$6.34 |
39.06 |
| 2021-12-31 |
233.36 |
$5.78 |
40.37 |
| 2021-09-30 |
227.30 |
$6.85 |
33.18 |
| 2021-06-30 |
224.15 |
$6.37 |
35.19 |
| 2021-03-31 |
223.34 |
$5.62 |
39.74 |
| 2020-12-31 |
229.05 |
$5.21 |
43.96 |
| 2020-09-30 |
212.26 |
$2.73 |
77.75 |
| 2020-06-30 |
217.54 |
$2.78 |
78.25 |
| 2020-03-31 |
208.22 |
$3.32 |
62.72 |
| 2019-12-31 |
245.65 |
$2.72 |
90.31 |
| 2019-09-30 |
227.78 |
$3.90 |
58.41 |
| 2019-06-30 |
226.25 |
$2.85 |
79.39 |
| 2019-03-31 |
223.48 |
$3.37 |
66.32 |
| 2018-12-31 |
201.01 |
$3.25 |
61.85 |
| 2018-09-30 |
232.10 |
$0.44 |
527.50 |
| 2018-06-30 |
212.42 |
$2.32 |
91.56 |
| 2018-03-31 |
191.52 |
$-0.46 |
0.00 |
| 2017-12-31 |
188.54 |
$1.31 |
143.93 |
| 2017-09-30 |
172.00 |
$4.65 |
36.99 |
| 2017-06-30 |
170.64 |
$3.50 |
48.75 |
| 2017-03-31 |
159.82 |
$6.05 |
26.42 |
| 2016-12-31 |
143.66 |
$6.03 |
23.82 |
| 2016-09-30 |
155.27 |
$4.51 |
34.43 |
| 2016-06-30 |
145.97 |
$5.26 |
27.75 |
| 2016-03-31 |
130.17 |
$3.75 |
34.71 |
| 2015-12-31 |
131.53 |
$3.27 |
40.22 |
| 2015-09-30 |
112.75 |
$3.41 |
33.06 |
| 2015-06-30 |
119.86 |
$4.10 |
29.23 |
| 2015-03-31 |
120.98 |
$5.46 |
22.16 |
| 2014-12-31 |
116.78 |
$5.83 |
20.03 |
| 2014-09-30 |
95.09 |
$6.00 |
15.85 |
| 2014-06-30 |
98.38 |
$4.93 |
19.96 |
| 2014-03-31 |
96.92 |
$4.80 |
20.19 |
| 2013-12-31 |
91.04 |
$4.74 |
19.21 |
| 2013-09-30 |
81.99 |
$6.50 |
12.61 |
| 2013-06-30 |
80.61 |
$7.47 |
10.79 |
| 2013-03-31 |
77.59 |
$7.54 |
10.29 |
| 2012-12-31 |
63.10 |
$7.54 |
8.37 |
| 2012-09-30 |
63.00 |
$5.62 |
11.21 |
| 2012-06-30 |
59.59 |
$5.55 |
10.74 |
| 2012-03-31 |
61.52 |
$5.49 |
11.21 |
| 2011-12-31 |
58.84 |
$5.48 |
10.74 |
| 2011-09-30 |
57.39 |
$5.63 |
10.19 |
| 2011-06-30 |
67.09 |
$5.95 |
11.28 |
| 2011-03-31 |
61.70 |
$5.71 |
10.80 |
| 2010-12-31 |
65.15 |
$5.57 |
11.70 |
| 2010-09-30 |
56.83 |
$5.51 |
10.31 |
| 2010-06-30 |
51.59 |
$5.12 |
10.08 |
| 2010-03-31 |
59.75 |
$5.22 |
11.45 |
| 2009-12-31 |
59.57 |
$5.04 |
11.82 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$48.912B |
$20.178B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
